Arcutis Biotherapeutics, Inc. Cash Flow Statement
ARQT / Health Care|8 years of annual SEC 10-K data (FY2018-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 8 fiscal years. All figures from audited SEC 10-K filings.
Arcutis Biotherapeutics, Inc. used $6M in operating cash flow and negative free cash flow of $6M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.65 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$16.1M | -$140.0M | -$262.1M | -$311.5M | -$206.4M | -$135.7M | -$42.0M | -$19.3M |
| Depreciation & Amortization | $700.0K | $600.0K | $800.0K | $622.0K | $454.0K | $122.0K | $68.0K | $0 |
| Operating Cash Flow | -$5.6M | -$112.2M | -$247.1M | -$257.7M | -$174.6M | -$113.0M | -$42.8M | -$14.1M |
| Capital Expenditures | $686.0K | $143.0K | $428.0K | $333.0K | $995.0K | $321.0K | $295.0K | $0 |
| Free Cash Flow | -$6.3M | -$112.3M | -$247.5M | -$258.0M | -$175.6M | -$113.4M | -$43.1M | -$14.1M |
| FCF Margin | -1.7% | -57.1% | - | - | - | - | - | - |